ELMSFORD, N.Y., Aug. 14, 2013 /PRNewswire/ -- BioScrip ®, Inc. (NASDAQ: BIOS) ("BioScrip") announced today the upsizing and pricing of the previously announced registered underwritten public offering of its common stock. The size of the offering has been upsized from the previously announced 6,800,000 shares to 6,895,873 shares, all of which will be sold by selling stockholders. The underwriter of this offering has been granted an option, exercisable within 30 days, to purchase up to an additional 1,020,000 shares of common stock from the selling stockholders on the same terms and conditions. BioScrip will not receive any of the proceeds from the initial sale of the shares of common stock or the sale of any additional shares pursuant to the option. (Logo: http://photos.prnewswire.com/prnh/20130117/NY44138LOGO) The offering is expected to close on or about August 19, 2013, subject to customary closing conditions. Morgan Stanley & Co. LLC is acting as the sole underwriter of the offering. A shelf registration statement, including a prospectus, with respect to the offering was previously filed by BioScrip with the Securities and Exchange Commission ("SEC") and became effective on April 4, 2013. A preliminary prospectus supplement relating to the offering has been filed with the SEC. The offering is being made only by means of a prospectus supplement and the accompanying base prospectus. When available, copies of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained without charge from Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by calling (866) 718-1649 or (917) 606-8474 or by emailing email@example.com. A copy of the prospectus supplement and the accompanying base prospectus may also be obtained without charge by visiting the SEC website at www.sec.gov. This press release is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.